2013年，全球糖尿病患者人數為3.82億，到2035年，估計有近5.92億人患有糖尿病。糖尿病是最常見的代謝紊亂之一，以胰島素分泌缺陷為特徵。免疫介導的胰腺b細胞破壞導致胰島素缺乏，最終導致I型糖尿病，而II型糖尿病的特點是胰島素抵抗和胰島素訊號的相對缺乏。高血糖是糖尿病併發症發生的主要原因。糖尿病涉及許多相互重疊和相互關聯的通路，導致潜在的致盲性併發症，如糖尿病視網膜病變和黃斑水腫[3]。糖尿病視網膜病變（diabeticretinopathy，DR）是糖尿病最廣泛的微血管併發症，也是全球範圍內導致視力下降的主要原因。全球約有9300萬DR患者、1700萬增殖性DR患者、2100萬糖尿病性黃斑水腫患者和2800萬VTDR患者。一項對35項基於人群的研究進行的新的系統回顧顯示，糖尿病患者中糖尿病視網膜病變、增生性糖尿病視網膜病變（PDR）和糖尿病黃斑水腫（DME）的患病率分別為34.6%、7.0%和6.8%。其特點是視網膜微血管中明顯形態异常的發展新增，這些异常要麼保持穩定，要麼發展為糖尿病性黃斑水腫或增生性糖尿病視網膜病變，這是導致勞動年齡成年人嚴重視力損害的主要原因，尤其是在工業化國家。糖尿病視網膜病變的嚴重程度從非增殖性和預增殖性到更嚴重的增殖性糖尿病視網膜病變，其中出現新血管的异常生長。一些預防或治療糖尿病視網膜病變和糖尿病性黃斑水腫（DME）的臨床試驗正在進行中。
Ref: https://www.hindawi.com/journals/bmri/2014/801269/
糖尿眼-多學科研證復康方案
- 藥物及其他醫療方案,請遵醫從醫生建議
- 飲食營養請依營養師指引
- 運動及或心理輔導,請參考各專家建議
- 為免錯誤診斷及漏診,請上傳最近一個月醫院的專業診斷報告,如證實是此症,則可參加試用期不如意退款計劃#。
可能適合的補充劑支援:
標準組合:
- 試用時期: 6 星期
# <試用期不如意退款計劃>,請參考相關文件
Diabetic Retinopathy
The number of people with diabetes worldwide was 382 million in 2013 and nearly 592 million people are estimated to be diabetic by 2035. Diabetes is one of the most common metabolic disorders, characterized by defective secretion of insulin. Immune mediated destruction of pancreatic b-cells leads to insulin deficiency and eventually to type I diabetes, while type II diabetes is characterized by insulin resistance and relative deficiency in insulin signaling. Hyperglycemia is recognized as a major responsible factor for the development of diabetic complications. Diabetes involves many overlapping and interrelated pathways that results in potentially blinding complications like diabetic retinopathy and macular edema. Diabetic retinopathy (DR) is the most widespread microvascular complication of diabetes and a major cause of vision loss worldwide. Globally, there are approximately 93 million people with DR, 17 million with proliferative DR, 21 million with diabetic macular edema, and 28 million with VTDR. A new systematic review of 35 population-based studies has revealed that the prevalence of diabetic retinopathy, proliferative diabetic retinopathy (PDR), and diabetic macular edema (DME) among diabetic patients is 34.6%, 7.0%, and 6.8%, respectively. It is characterized by the increased development of distinct morphological abnormalities in the retinal microvasculature that either remains stable or progresses to diabetic macular edema or proliferative diabetic retinopathy, which are leading causes of severe visual impairment in working-age adults especially in industrialized countries. The severity of diabetic retinopathy ranges from nonproliferative and preproliferative to more severely proliferative diabetic retinopathy, in which the abnormal growth of new vessels occurs. A number of clinical trials on the prevention or treatment of diabetic retinopathy and diabetic macular edema (DME) are in progress.
Multidisciplinary research and rehabilitation program for Diabetic Retinopathy
- Please follow the doctor's advice for drugs and other medical plans
- Please follow the guidance of nutritionist
- For sports or psychological counseling, please refer to the experts' suggestions
- In order to avoid misdiagnosis and missed diagnosis, please upload the professional diagnosis report of the hospital in the latest month. If it is confirmed to be this disease, you can participate in the
.#
Possible supplements supporting:
Standard combination:
Trial period: 6 weeks
# Please refer to the relevant documents for the
If you have this disease, please follow your doctor's complete medical plan. You must consult the attending doctor before using the multidisciplinary rehabilitation plan. If your attending doctor does not recommend you to join the supplement conditioning combination, please do not use it. If you need to seek second opinion from other doctors, you can contact our online "Doctors Without Borders", or another professional doctor in your own city.